Biosimilars in India: Regulatory Pathway & Clinical Guide

This piece covers how that regulatory pathway actually works, how a similar biologic differs scientifically from a plain generic, what the approval process demands from a manufacturer, and what a treating clinician or hospital pharmacy should weigh before substituting one biologic for another.

What exactly is a biosimilar?

A biosimilar is a biologic medicine shown through head-to-head comparison to be highly similar in quality, safety and efficacy to an already-approved reference biologic, though not identical to it at the molecular level the way a small-molecule generic is. The World Health Organization's guidelines on similar biotherapeutic products, revised in 2022, set the international scientific framework most national regulators including India's draw from.

The distinction from a generic matters clinically. A generic copies a simple chemical molecule exactly; a biosimilar approximates a large, complex protein produced in a living cell line, where batch-to-batch variation exists even in the original reference product itself. That is why biosimilar approval leans on comparability data rather than proof of an identical structure.

How does CDSCO actually regulate similar biologics in India?

CDSCO, jointly with the Department of Biotechnology and the Review Committee on Genetic Manipulation, regulates similar biologics under the 2016 "Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India," which replaced earlier draft guidance from 2012. Approval requires a tiered dossier: analytical and functional characterisation first, then preclinical toxicology, then clinical pharmacokinetic and immunogenicity data, and confirmatory efficacy trials where the analytical package alone can't establish similarity.

The 2016 framework was itself the product of an earlier controversy: a 2016 report by international health advocacy groups had flagged that some Indian "similar biologics" approved before 2012 were licensed with limited or no comparative clinical data against the reference product. The tightened post-2016 pathway responded directly to that gap, requiring a defined comparability exercise for every new similar biologic rather than leaving evidentiary depth to case-by-case discretion.

A three-member committee spanning CDSCO, RCGM and DBT reviews applications jointly rather than any single body signing off alone. This layered review is specific to India and differs from the single-regulator model used by the US FDA or EMA.

Why does India approve so many biosimilars, and does that affect quality?

India has approved similar biologics across oncology, diabetes and autoimmune disease for over two decades, well ahead of most Western regulators, driven partly by a large addressable patient population priced out of originator biologics and partly by an established domestic biotech manufacturing base. Approval volume alone says nothing about individual product quality — each similar biologic still has to clear the same comparability dossier described above.

The practical effect for a prescriber is that India carries far more biosimilar options per originator molecule than the US or EU markets do, particularly for monoclonal antibodies used in oncology. That breadth is a genuine access advantage, but it also means the depth of the comparability package varies more across products than in markets with fewer, later approvals subject to more mature post-marketing surveillance data.

Is switching a patient from an originator biologic to a biosimilar clinically safe?

Current evidence does not show increased immunogenicity or loss of efficacy from switching a stable patient from an originator biologic to its biosimilar, according to regulatory reviews synthesising over a decade of European post-marketing data. The theoretical concern is antibody formation triggered by minor structural differences on switch.

In practice, regulators treat the risk of switching to a biosimilar as no greater than switching between two manufacturing batches of the same reference biologic. That said, "switching" is a decision that belongs with the treating clinician managing the specific patient and molecule, not a default pharmacy substitution — India does not currently have a formal interchangeability designation separate from marketing approval, unlike the tiered system some other regulators use.

Which biosimilar India categories are most established in the market?

Oncology monoclonal antibodies — trastuzumab and rituximab biosimilars in particular — and insulin analogues carry the longest track record among Indian-approved similar biologics, several with over a decade of post-marketing use. Filgrastim and other supportive-care biologics for chemotherapy-induced neutropenia also have a long domestic history.

Newer biosimilar India categories, including some autoimmune-disease monoclonal antibodies, have shorter domestic post-marketing histories even where the reference molecule itself is well established internationally. A prescriber evaluating a newer biosimilar should weigh how long that specific product, not just the originator molecule, has been in Indian clinical use.

What should a hospital weigh before adding a biosimilar to its formulary?

A formulary committee should look at the comparability data behind that specific manufacturer's biosimilar, not just the reference molecule's reputation, and track the batch and manufacturer at patient level for immunogenicity monitoring. CDSCO approval clears the regulatory bar; it doesn't substitute for a hospital's own pharmacovigilance once the drug is in routine use.

Cost is frequently the deciding factor in formulary selection given the price gap between reference biologics and their biosimilars, but a hospital that treats every biosimilar as interchangeable without batch-level tracking loses the ability to trace an adverse event back to a specific product later. That tracking discipline sits squarely with whichever pharmacy actually dispenses and records the drug inside the hospital.

A hospital's own in-house pharmacy is what makes that batch-level tracking possible in the first place. When a high-cost biologic or its biosimilar isn't reliably in stock inside the hospital, the prescription moves to an outside chemist, and with it goes the continuity of record that formulary-level pharmacovigilance depends on — plus the revenue that would have stayed with the institution. Medyzen's managed hospital pharmacy model is built around exactly this kind of reliable in-house stocking, and our piece on prescription leakage covers what walks out the door, and what it costs a hospital, when a prescribed drug isn't on the shelf. Our companion guide on biosimilar cost in India breaks down the price gap that makes formulary decisions like this one matter in the first place.

Sources

1. 1Guidelines on Similar Biologics 2016 — CDSCO and Department of Biotechnology, Government of India
2. 2WHO Guidelines on Evaluation of Biosimilars — World Health Organization, Annex 3, 2022
3. 3Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective — National Institutes of Health, National Library of Medicine
4. 4Are we ready to close the discussion on the interchangeability of biosimilars? — Drug Discovery Today, peer-reviewed
5. 5Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945

This article is for informational purposes and is not a substitute for professional medical advice. It describes drug classes, regulatory pathways and clinical evidence at a general level; it is not a recommendation for or against any specific product or patient. Consult the treating clinician before any biosimilar substitution decision.